Navigation Links
3-D tumor models improve drug discovery success rate
Date:7/20/2012

Imagine millions of cancer cells organized in thousands of small divots. Hit these cells with drugs and when some cells die, you have a candidate for a cancer drug. But a review published this week in the journal Expert Opinion on Drug Discovery argues that these 2D models in fact offer very little information about a potential drug's effects in the body and may often give researchers misleading results.

"Up until the 1980s animal models were the standard for cancer drug discovery. However, with the increase in the number of compounds available for testing and the advent of high-throughput screening (HTS), the use of animals to discover cancer drugs became too costly and unethical. Consequently, 2D cell culture models have become the mainstay for drug discovery or to explore a drug's mechanism of action," says Dan LaBarbera, PhD, investigator at the University of Colorado Cancer Center and the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences. LaBarbera is principal investigator of the recent review, on which he collaborated with Skaggs colleagues Brian Reid, PhD, and Byong Hoon Yoo, PhD.

LaBarbera cites the gap between results in 2D cells and effects in tumors themselves as a contributing factor for the declining rate of drugs passing FDA approval. In particular, only 5 percent of investigational new drugs targeting cancer make it through clinical trials, at a cost of about $800 million per drug. When you factor in the inevitable failures at various points in development, each approved drug costs an average $1.5 billion.

To increase the drug success rate, LaBarbera suggests something called the multicellular tumor spheroid (MCTS) model. In these models, instead of 2D monolayers, cancer cells are cultured as 3D spheroids. One of the advantages of the MCTS model is that when spheroids reach a critical diameter, they begin to form an outer proliferating zone, an inner quiescent zone, and a central necr
'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. The loss of a protein makes jump the tumor to the lymph node
2. Nanotherapy: Treating deadly brain tumors by delivering big radiation with tiny tools
3. Dental X-rays linked to common brain tumor
4. TGen leads new National Institutes of Health study of brain tumors
5. Immune-response genes affecting breast tumor eradication
6. A single stem cell mutation triggers fibroid tumors
7. Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers
8. Cancerous tumors deliver pro-metastatic information in secreted vesicles
9. Researchers identify need to sample multiple tumor zones in breast cancer
10. Tumor microenvironment helps skin cancer cells resist drug treatment
11. BGI debuts new tool PDXomics for tumor xenograft research and applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... DENVER , Aug. 20, 2014  The ... take place in Tampa, Florida ... interactive sessions with Steven Rahman, Director, Technology and Strategy ... Sector at Experian. The theme of this year,s ... and Privacy. "Biometrics UnPlugged: Mobility ...
(Date:8/19/2014)... Can nutrition rating systems be used in supermarkets to ... University researchers sought to answer that very question by ... uses the Guiding Stars System to rate the nutritional ... Cornell Food and Brand Lab,s David Just, PhD, and ... studied the sales records of over 150 Hannaford Supermarkets ...
(Date:8/19/2014)... not a lemur. It,s not an African Bush Baby or ... adorable and downright "cool" primate from Southeast Asia. , "It,s ... said Rafe Brown, curator-in-charge at the University of Kansas, Biodiversity ... cute, furry body; a long tail with a furry tuft ... that look a bit like the disks on the digits ...
Breaking Biology News(10 mins):Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... American eels are fast disappearing from restaurant menus as ... the reasons for the eel decline remain as mysterious ... NOAA scientist and colleagues in Japan and the United ... primary factor in declining reproduction and survival rates. ...
... Matyjaszewski have created a version of Harry Potters famed invisibility cloak for ... Through a collaborative effort, ... developed a new design paradigm that makes particles invisible. , ... In a recent edition of Advanced ...
... cancer immune therapy have made an unexpected find: They,ve ... inflammatory bowel disease (IBD), a cluster of conditions that ... and diarrhea. , The two most common forms ... in extreme cases, they can be fatal. The mouse ...
Cached Biology News:Changes in ocean conditions in Sargasso Sea potential cause for decline in eel fishery 2Changes in ocean conditions in Sargasso Sea potential cause for decline in eel fishery 3Carnegie Mellon researchers create invisibiity cloak 2Scientists successfully treat new mouse model of inflammatory bowel disease 2
(Date:8/19/2014)... GLEN BURNIE, Md. , Aug. 19, 2014 /PRNewswire/ ... the clinical research industry, recently announced the formation of ... is pleased to announce the addition of Dr. ... Photo - http://photos.prnewswire.com/prnh/20140818/136957 ... insight across a variety of therapeutic areas and set ...
(Date:8/19/2014)... 2014 Sales Horizons, a leader in ... online sales skills training course to help companies ... clinical staff spend the majority of their time on ... center, or physician practice – providing support and education ... there? Sales Horizons believes clinical staff are and should ...
(Date:8/18/2014)... Aug. 18, 2014 BioElectronics Corporation ... consumer medical devices said that its EVP ... by CEOLIVE.TV as part of its Executive ... is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... to investors the unique advantages of BioElectronics ...
(Date:8/18/2014)... NEW YORK , August 18, 2014 /PRNewswire/ ... report published by Transparency Market Research "Life Science ... Culture, Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents ... Research and Academic Institutions, Clinical Laboratories, and Forensic ... and Forecast, 2013 - 2019", the global life ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5
... BPUR ) today announced its financial results for ... quarter, the company reported a net,loss of $5.8 million, ... loss,of $6.9 million, or $0.53 per common share, for ... on January 31, 2008 and 2007 were,34,971,087 and 15,543,025, ...
... on March 13, 2008 at 9:00 am (Eastern) ... / 6:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong), ... Inc. (NYSE: WX ) ("WuXi PharmaTech" or "the ... company, today announced that it will release unaudited,financial results ...
... Sweden, February 21 With two successful,international ... a new expansion phase. The share issue ... number of significant product,launches in 2008-2009. These ... leading global pharmaceutical companies to meet the,industry,s ...
Cached Biology Technology:Biopure Announces 2008 First Quarter Financial Results 2Biopure Announces 2008 First Quarter Financial Results 3Biopure Announces 2008 First Quarter Financial Results 4Biopure Announces 2008 First Quarter Financial Results 5Biopure Announces 2008 First Quarter Financial Results 6Biopure Announces 2008 First Quarter Financial Results 7WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008 2
... Varioskan is a high performance spectral ... and incubator. With the advanced SkanIt ... reliability for drug discovery assay development. ... fluorescence intensity, time-resolved fluorescence and photometric ...
Immulon 2 HB 1x8 Strip assembled, C-bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
... The Jouan RCT series of refrigerated cold ... to trapping of low volatility/aqueous solvents or ... RC10 and other vacuum concentrators/centrifugal evaporators. Also ... cooling systems such as used in electron ...
Immulon 2HB, Flat Bottom, 50/Bx; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
Biology Products: